Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion

Inclusion criteria

• Male or female subjects aged > 50
• Presence of focal vitreomacular adhesion measured by Optical Coherence Tomography (OCT).
• Diagnosis of active primary or recurrent subfoveal CNV secondary to AMD, including those with predominantly classic, minimally classic or occult lesions with no classic component.
• The total area of Choroidal Neovascularization (CNV) (including both classic and occult components) encompassed within the lesion must be > 50% of the total lesion area
• The total lesion area must be < 12 disc areas
• Subjects who have previously received at least three antiangiogenic injections(Lucentis® or Avastin®) in the study eye.
• Subjects with visual acuity of 20/32 to 20/200 in the study eye
• Written informed consent obtained from the subject prior to inclusion in the study

Exclusion criteria

• Evidence of complete macular Posterior Vitreous Detachment (PVD) in the study eye on biomicroscopy, B-scan ultrasound or OCT prior to planned study drug injection
• Subjects with vitreous haemorrhage which precludes either of the following: visualization of the posterior pole by visual inspection or adequate assessment of the macula by either OCT and/or fluorescein angiography in the study eye or other opacities precluding visualisation of the fundus.
• Subjects who have previously received more than 9 antiangiogenic agent injections (whether Lucentis® or Avastin® or other anti-angiogenic agent) in the study eye
• Subjects with history of rhegmatogenous retinal detachment or proliferative vitreoretinopathy (PVR) in the study eye
• Subjects with high myopia (> 8D) or aphakia in the study eye
• Subjects who have had ocular surgery in the study eye in the prior three months
• Subjects who have had a vitrectomy in the study eye at any time.